Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash from Financing Activities of $9.1 million for Q1 2026, up 396.5% year-over-year from $1.8 million in Q1 2025, and down 47.81% quarter-over-quarter from $17.5 million in Q4 2025.
Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Scilex Holding's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 396.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 167.54% YoY), while the FY2025 annual figure was -$5.5 million, up 69.88% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $9.1 million, down from $17.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $43.5 million in Q2 2023, with the low at -$38.9 million in Q3 2023.
- The 5-year median for Cash from Financing Activities is -$3.1 million (2025), against an average of $1.8 million.
- Peak annual rise in Cash from Financing Activities reached 1849.77% in 2023, while the deepest fall reached 466.26% in 2023.
- Scilex Holding's Cash from Financing Activities stood at $426000.0 in 2022, then soared by 1849.77% to $8.3 million in 2023, then tumbled by 186.48% to -$7.2 million in 2024, then surged by 343.91% to $17.5 million in 2025, then slumped by 47.81% to $9.1 million in 2026.
- Business Quant data shows SCLX's Cash from Financing Activities at $9.1 million in Q1 2026, $17.5 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -4.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.14 Mn |
| Mar 31, 2026 | 9.14 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Dec 31, 2023 | 8.31 Mn |